Insights

2 fantastic ASX healthcare shares to buy for 2021

CSL Limited (ASX:CSL) and this ASX healthcare share could be top options for Australian investors in 2021 and beyond…
The post 2 fantastic ASX healthcare shares to buy for 2021 appeared first on The Motley Fool Australia. –

Doctor with stethoscope in hand and data graph showing upward trend

Due to ageing populations, better technologies and treatments, and increasing chronic disease burden, demand for healthcare services is expected to continue to increase over the next few decades.

This bodes well for healthcare shares and has many tipping them to continue to outperform over the long term.

Two healthcare shares that are highly rated are listed below:

CSL Limited (ASX: CSL)

CSL is one of the world’s leading biotherapeutics companies. It is made up of the high quality CSL Behring and Seqirus businesses. CSL Behring is the global leader in plasma therapies and Seqirus is the second largest influenza vaccines business.

Both businesses have been growing at a solid rate in recent years and have been tipped to continue doing so in the future. This is due to their leading therapies and lucrative research and development pipelines.

CSL’s pipeline contains a number of highly promising products that have the potential to generate significant revenues in the future. This includes clazakizumab, which is being developed to treat kidney transplant rejection. This product alone could generate peak sales of US$5.4 billion eventually.

UBS recently retained its buy rating and $346.00 price target on CSL’s shares. This compares to the latest CSL share price of $304.14.

ResMed Inc. (ASX: RMD)

ResMed has been growing at a such a strong rate over the last decade it has now become one of the world’s leading sleep treatment companies. Pleasingly, it has started the new decade just as strongly as it finished the last. In FY 2020, it delivered a 15% increase in revenue to US$2,957 million and a 32% jump in net income to US$692.8 million.

The good news is that it has started FY 2021 strongly and appears well-placed to continue this positive form in the future. This is thanks to its world-class products and the massive number of undiagnosed sleep apnoea sufferers globally.

The company also has a rapidly growth digital health ecosystem, which reached over 12 million cloud connectable medical devices in 2020. This provides ResMed with strong recurring revenues and a material amount of high quality data.

Last month Credit Suisse put an outperform rating and $31.00 price target on ResMed’s shares. This compares to the current ResMed share price of $28.58.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of June 30th

More reading

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post 2 fantastic ASX healthcare shares to buy for 2021 appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!